Τίτλος:
Changes of circulating MicroRNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Context: Expression of microRNAs (miRs) related to bone metabolism in the serum may be affected by antiosteoporotic treatment. Objective: To investigate the effect of two antiosteoporotic agents with opposite effects on bone metabolism on miR expression profile in the serum. Design: Observational, open label, nonrandomized clinical trial. Setting: The outpatient clinics for Metabolic Bone Diseases of 424 General Military Hospital, Thessaloniki, Greece. Patients and Interventions: Postmenopausal women with low bone mass were treated with either teriparatide (TPTD; n = 30) or denosumab (n = 30) for 12 months. Main Outcome Measures: Changes in the serum expression of selected miRs linked to bone metabolism at 3 and 12 months of treatment. Secondary measurements: associations of measured miRs with changes in bone mineral density (BMD) at 12 months and the bone turnover markers (BTMs) C-terminal cross-linking telopeptide of type I collagen and procollagen type I N-terminal propeptide at 3 and 12 months. Results: We found significantly decreased relative expression of miR-33-3p at 3 months (P = 0.03) and of miR-133a at 12 months (P = 0.042) of TPTD treatment. BMD values at 12 months of TPTD treatment were significantly and inversely correlated with miR-124-3p expression at 3 months (P = 0.008). Relative expression of miR-24-3p and miR-27a was correlated with changes in BTMs during TPTD treatment and of miR-21-5p, miR-23a-3p, miR-26a-5p, miR-27a, miR-222-5p, and miR-335-5p with changes in BTMs during denosumab treatment. Conclusions: Circulating miRs are differentially affected by treatment with TPTD and denosumab. TPTD affects the relative expression of miRs related to the expression of RUNX-2 (miR-33) and DKK-1 gene (miR-133). Copyright © 2018 Endocrine Society.
Συγγραφείς:
Anastasilakis, A.D.
Makras, P.
Pikilidou, M.
Tournis, S.
Makris, K.
Bisbinas, I.
Tsave, O.
Yovos, J.G.
Yavropoulou, M.P.
Περιοδικό:
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Εκδότης:
Oxford University Press
Λέξεις-κλειδιά:
circulating microRNA; collagen type 1; denosumab; microRNA; microRNA 124 3p; microRNA 133a; microRNA 21 5p; microRNA 222 5p; microRNA 23a 3p; microRNA 24 3p; microRNA 26a 5p; microRNA 27a; microRNA 33 3p; microRNA 335 5p; parathyroid hormone[1-34]; protein precursor; unclassified drug; biological marker; bone density conservation agent; circulating microRNA; collagen type 1; collagen type I trimeric cross-linked peptide; denosumab; DKK1 protein, human; parathyroid hormone[1-34]; peptide; peptide fragment; procollagen; procollagen Type I N-terminal peptide; RUNX2 protein, human; signal peptide; transcription factor RUNX2, adult; aged; amino terminal sequence; Article; bone density; bone metabolism; bone turnover; carboxy terminal sequence; clinical trial; correlational study; drug effect; drug efficacy; female; gene expression; Greece; human; major clinical study; observational study; open study; outpatient department; postmenopause osteoporosis; priority journal; protein cross linking; public hospital; treatment response; blood; bone remodeling; middle aged; postmenopause osteoporosis; treatment outcome; very elderly, Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Circulating MicroRNA; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Denosumab; Female; Humans; Intercellular Signaling Peptides and Proteins; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Teriparatide; Treatment Outcome
DOI:
10.1210/jc.2017-02406
